The launch of the 750mcg teriparatide solution in Australia has seen controlled distribution to date. Primarily designated for patients with severe bone loss who have not responded to other treatments , access is carefully managed. Existing supply amounts are constrained , and individuals should verify regarding their physician the recent details o